These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 11894120

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H, Yu D, Agrawal S, Zhang R.
    Prostate; 2003 Feb 15; 54(3):194-205. PubMed ID: 12518324
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
    Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R.
    Mol Med; 2002 Apr 15; 8(4):185-99. PubMed ID: 12149568
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. MDM2 oncogene as a target for cancer therapy: An antisense approach.
    Wang H, Zeng X, Oliver P, Le LP, Chen J, Chen L, Zhou W, Agrawal S, Zhang R.
    Int J Oncol; 1999 Oct 15; 15(4):653-60. PubMed ID: 10493945
    [Abstract] [Full Text] [Related]

  • 9. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R.
    Ann N Y Acad Sci; 2003 Dec 15; 1002():217-35. PubMed ID: 14751837
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F, Tortora G.
    Clin Cancer Res; 2004 Jul 15; 10(14):4858-64. PubMed ID: 15269162
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.
    Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD.
    PLoS One; 2013 Jul 15; 8(3):e58089. PubMed ID: 23520486
    [Abstract] [Full Text] [Related]

  • 19. Chemosensitization by antisense oligonucleotides targeting MDM2.
    Bianco R, Ciardiello F, Tortora G.
    Curr Cancer Drug Targets; 2005 Feb 15; 5(1):51-6. PubMed ID: 15720189
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
    Guo B, Cao S, Tóth K, Azrak RG, Rustum YM.
    Clin Cancer Res; 2000 Feb 15; 6(2):718-24. PubMed ID: 10690558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.